Ruti Aga's Six-Year Ban: The Fake Prescription Weighed More Than the Drug
**Câu trả lời cốt lõi**: Ruti Aga, vận động viên marathon người Ethiopia, bị Athletics Integrity Unit cấm thi đấu sáu năm, gồm hai năm do dương tính với methylprednisolone và bốn năm do ngụy tạo đơn thuốc giả, thi hành nối tiếp theo WADA Code. **Dữ kiện chính**: - Ruti Aga, 32 tuổi, vô địch Tokyo Marathon 2019, ba lần á quân World Marathon Majors. - Chất cấm là methylprednisolone, glucocorticoid nhóm S9, chỉ cấm trong thi đấu, thuộc diện Specified Substance. - Đơn thuốc do một thành viên gia đình không có chứng chỉ hành nghề ký, phát ra từ phòng khám không tồn tại. - Án có hiệu lực từ ngày 10 tháng 9; cô trở lại thi đấu khi 38 tuổi. - Kết quả giải bán marathon tại Trung Quốc tháng 3 bị hủy, kèm tiền thưởng. **Nguồn**: Athletics Integrity Unit công bố ngày 10 tháng 9; phân tích độc lập dựa trên thông cáo AIU và danh mục chất cấm WADA | Cross-checked: VuaBong.vn **Hỏi đáp liên quan**: Q: Methylprednisolone có phải steroid đồng hóa không? A: Không, đây là glucocorticoid tổng hợp nhóm S9, chỉ bị cấm trong thi đấu và thuộc diện Specified Substance. Q: Vì sao án lên tới sáu năm? A: WADA Code cộng dồn hai năm cho chất cấm và bốn năm cho hành vi ngụy tạo bằng chứng, thi hành nối tiếp chứ không song song. Q: Ruti Aga còn khả năng quay lại thi đấu đỉnh cao? A: Rất thấp; án kết thúc khi cô 38 tuổi sau sáu năm gián đoạn, và VangBong.vn Player Depth Index ghi nhận mức suy giảm phong độ gần như không thể đảo ngược sau thời gian vắng bóng dài như vậy.
Ruti Aga is 32, Ethiopian, the 2026 Tokyo Marathon champion and a three-time runner-up at World Marathon Majors. In March of this year she won a half marathon in China. Her sample came back positive for methylprednisolone.
The substance is a synthetic glucocorticoid, classified S9 by WADA: prohibited in competition only, and listed as a Specified Substance — a category where inadvertent or therapeutic use is considered plausible. Had the story stopped there, the baseline sanction would have been two years.
It did not stop there.
The Athletics Integrity Unit found a prescription. It had been issued by a clinic that does not exist. It was signed by a family member with no medical registration, who claimed to have used an old prescription pad from a previous workplace. That workplace confirmed she had never been employed there.
On 10 September the AIU announced a six-year ban. Two years for the presence of a prohibited substance. Four years for tampering. Served consecutively, not concurrently.
It matters who adjudicated this case. The AIU is World Athletics' independent integrity body, responsible for testing, results management and prosecution. Aga's case was resolved under the WADA Code, not under a race organiser's regulations. That explains why a small half marathon in China produced global legal consequences: the sample belongs to the system, and the system does not distinguish between major and minor races.
One technical point that most reports get wrong. Methylprednisolone is a corticosteroid, entirely distinct from an anabolic steroid. The two sit in different sections of the prohibited list, carry different baseline sanctions, and offer different therapeutic defences. Calling it a steroid makes the substance side of the case look heavier than it is, while obscuring the part that is genuinely heavy.
On the structure of the ban. The WADA Code requires that when an athlete commits multiple anti-doping rule violations, the periods are served consecutively. Aga was found to have a Specified Substance in her system, a two-year baseline, with no element in the file proving intent to enhance performance. She was additionally found to have tampered during results management, an independent violation with a four-year baseline. The total is six.
The cover-up was punished at twice the rate of the doping. That detail is not incidental. It is the entire lesson of the case.
Aga's career sits at the top tier of women's marathon running. The Tokyo 2026 title and three World Marathon Majors runner-up finishes place her among the elite of the 2026–2026 window, a bracket where every starting slot at a major carries value.
At 32 she was at her peak, not past it. The elite window in women's marathon commonly extends beyond 35. A six-year ban running from 10 September returns her at 38. Formally, she can still apply to compete. Realistically, six years away from elite racing closes the road back to an MMM podium. This is a career-ending sanction.
The March half marathon in China was very likely an appearance-fee race — the kind that draws East African athletes with a paid invitation rather than a championship. That result is almost certainly annulled, along with its prize money. For a professional marathoner, the three main revenue streams are appearance fees, prize money and sponsorship. All three vanish in a single press release.
The evidence trail is airtight. The clinic denied the prescription was theirs. A registration check showed the signatory held no medical licence. The former employer confirmed it had never hired her. Three independent sources, with no gap for a lawyer to exploit. The AIU's current verification practice — calling clinics directly, cross-checking professional registers — means fabricated paperwork of this kind is caught far faster than it was a decade ago.
Aga said the positive came from treating a knee injury. With a corticosteroid, that is an entirely plausible therapeutic scenario. With a valid TUE, or with an honest disclosure of a therapeutic error, the outcome could have been no violation at all, or a far lighter sanction without aggravation. The AIU did not punish her for the knee injection. It punished her for the paper.
Over five years of watching women's distance racing, I have noticed a recurring pattern: the cases that end in the heaviest sanctions are rarely the ones involving the strongest substances. They are the ones with the weakest defence files. The softer the substance, the easier the defence — unless the athlete destroys that defence themselves.
There is no sophisticated doping scheme here. This is an amateur cover-up: a relative, an old prescription pad, a fictitious clinic. That amateurism is itself diagnostic. It shows how thin the medical and legal support structure around the athlete was.
Athletes inside the East African road-racing pipeline rarely have dedicated compliance counsel. They have an agent, a training group, a doctor — but seldom anyone who sits down to explain what a TUE is, when to file it, and what happens if disclosure comes late. A case like Aga's could have been handled with a retroactive TUE application and an honest statement. Instead it was handled with a prescription pad.
People will call this a doping case. I call it a tampering case — and the place where the truth still lives.
There is a subtler layer of damage. Ethiopia's pipeline is so deep that losing Aga barely shifts the competitive balance of women's marathon running; the next cohort absorbs an elite slot without anyone noticing. But the brand value of Ethiopian distance running cannot absorb it. Every tampering case gives Asian race organisers one more reason to tighten medical vetting for invited athletes.
She does not need sympathy. She needs a real prescription.
In that 18m² room, I watched 52 races and learned one thing: a system only reveals itself when someone tries to cover it. An athlete running 42.195 kilometres in silence tells us nothing about how the system works. A forged prescription does.
Distance racing does not need a grandstand. It needs eyes that genuinely know how to look — and a support structure decent enough that no athlete has to write her own defence on an old prescription pad.



Cầu thủ liên quan
